Hot Stock shakes up Big Pharma! BioNxt Solutions aims to replace Ozempic weight loss injection!

Stock poised for next price jump

BioNxt's stock has impressively demonstrated its strength in recent weeks. Starting at EUR 0.35 at the end of July, the share launched a spectacular rally, climbing to EUR 0.66 in a short time before undergoing a healthy consolidation to its current level of EUR 0.53. From both a technical and fundamental perspective, the period of calm could now be over, as the conditions for the next price surge are in place.

Innovations for new drug delivery formats

What makes this German-Canadian company so exciting? BioNxt is developing modern drug delivery systems designed to make medications more accessible to patients while also improving their effectiveness. In addition to transdermal patches and traditional tablets, the Company focuses particularly on oral dissolvable films that dissolve directly in the mouth, enabling rapid absorption. The concept of releasing chemotherapeutic agents directly at the tumor site further underscores its patient-centered approach. The goal is to reduce side effects and increase treatment adherence—a crucial factor in managing chronic diseases. With this strategy and consistent protection through international patents, BioNxt is positioning itself in high-growth markets.

Melting Ozempic instead of injecting it

BioNxt Solutions' latest project is working on a dissolvable film formulation of semaglutide. The active ingredient is at the heart of Novo Nordisk's blockbuster drugs Ozempic and Wegovy for obesity and diabetes, which generate billions in revenue – and the trend is still rising. BioNxt's goal is to develop an oral dosage form that absorbs the active ingredient through the oral mucosa, thereby replacing injections. If this step is successful, a patent could soon follow – a milestone that would make the Company an attractive target for partnerships with industry giants or even acquisitions. The timing is favorable: Novo Nordisk and Eli Lilly currently dominate the market, but demand significantly exceeds production capacity. The market for obesity drugs is far from saturated. According to analysts, the industry could generate around USD 150 billion in revenue by the end of the decade. Nearly all medications must be injected - a barrier for many patients. An easy-to-take, effective orally disintegrating film variant could therefore significantly increase willingness to undergo treatment and position BioNxt as an innovative player in one of the most lucrative pharmaceutical segments.

Several milestones achieved recently

But BioNxt has even more exciting projects in the pipeline. Several milestones were achieved over the summer. At the end of July, a prototype of the lead candidate BNT23001 was presented – a cladribine dissolvable film formulation for multiple sclerosis. Initial tests confirmed consistent quality, rapid disintegration times and stable drug loading. This could make a decisive difference, especially for MS patients, who often suffer from swallowing disorders. Shortly thereafter, BioNxt reported significant progress in the patent field: Both the European Patent Office and the Eurasian Organization confirmed key property rights for the technology. At the same time, an accelerated procedure is underway in the US, which could lead to a patent being granted within a year. This is flanked by a platform patent that secures the dissolvable film technology far beyond cladribine. Looking ahead to the coming months, management anticipates preclinical data and further partnerships that will strengthen the foundation for clinical development and market entry.

Conclusion: New share price rally and takeover speculation

With its innovative dissolvable film technologies, BioNxt Solutions has positioned itself in a way that makes the Company exciting for investors and potential partners alike. While the development of an oral version of Ozempic is making headlines, the progress in MS therapy with cladribine and the secure patent strategy show that BioNxt has a solid foundation. With a comparatively low valuation and several projects in growth markets, the stock could benefit from further milestones in the near future – and Big Pharma is likely to be watching very closely.